Genome

Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL

Retrieved on: 
Friday, October 15, 2021

SAN DIEGO, Oct. 14, 2021 /PRNewswire/ --Illumina, Inc. (NASDAQ:ILMN) today announced that Bob Ragusa has been appointed as Chief Executive Officer of GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, effective immediately.

Key Points: 
  • SAN DIEGO, Oct. 14, 2021 /PRNewswire/ --Illumina, Inc. (NASDAQ:ILMN) today announced that Bob Ragusa has been appointed as Chief Executive Officer of GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, effective immediately.
  • GRAIL currently operates as a separate and independent unit of Illumina.
  • Hans Bishop, who has been Chief Executive Officer since June 2019, has chosen to step down and will serve as Advisor to Bob Ragusa through the end of 2021.
  • As Illumina's Chief Operations Officer, he was responsible for significantly scaling the business to serve over seven thousand customers in more than 140 countries.

Global Genomics Market Research Report 2021: Focus on Functional Genomics & Pathway Analysis - Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 14, 2021

The "Global Genomics Market Size, Share & Trends Analysis Report by Application & Technology (Functional Genomics, Pathway Analysis), by Deliverable (Products, Services), by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genomics Market Size, Share & Trends Analysis Report by Application & Technology (Functional Genomics, Pathway Analysis), by Deliverable (Products, Services), by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • This has also led to an increase in the market competition, coupled with the development of breakthrough genomic technologies by Veritas Genetics, 23andMe, and other key players.
  • In August 2020, Ancestry launched a new next-generation sequencing-based tool to screen genes linked to blood disorders, colon cancer, heart diseases, and breast cancer.
  • This product, developed by Quest Diagnostics, has a better DNA analysis efficiency when compared to microarray-based testing.

Study Shows the Combination of OGM and NGS with Linked-Reads Detects Significantly More Clinically Relevant Variants Resulting in Higher Success Rates for Resolving Previously Unclassified Subjects in Genetic Disease Research

Retrieved on: 
Thursday, October 14, 2021

The authors also identified candidate variants in another 60% (18 of 30 cases) for future follow-up.

Key Points: 
  • The authors also identified candidate variants in another 60% (18 of 30 cases) for future follow-up.
  • FGA provides information beyond current assays and results in higher resolution genome maps that can be used for future studies.
  • Fifty percent of the participants in this study had clinically relevant variants hidden in their genomes that WES alone had not uncovered.
  • We believe there is tremendous potential in using OGM together with NGS to understand disease from the very beginning of any study.

Illumina to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021

Retrieved on: 
Wednesday, October 13, 2021

SAN DIEGO, Oct. 13, 2021 /PRNewswire/ --Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the third quarter 2021 following the close of market on Thursday, November 4, 2021.

Key Points: 
  • SAN DIEGO, Oct. 13, 2021 /PRNewswire/ --Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the third quarter 2021 following the close of market on Thursday, November 4, 2021.
  • The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, November 4, 2021.
  • Interested parties may access the live teleconference through the Investor Info section of Illumina's website under the "company" tab at www.illumina.com .
  • To learn more, visit www.illumina.com and connect with us on Twitter , Facebook , LinkedIn , Instagram , and YouTube .

Syros Reports Inducement Grant to Chief Financial Officer under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, October 13, 2021

Syros Pharmaceuticals (Nasdaq: SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option award to Jason Haas, the Companys recently hired Chief Financial Officer, in accordance with Mr. Haass employment offer letter.

Key Points: 
  • Syros Pharmaceuticals (Nasdaq: SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option award to Jason Haas, the Companys recently hired Chief Financial Officer, in accordance with Mr. Haass employment offer letter.
  • The grant was approved by the Companys Board of Directors and was made as a material inducement to Mr. Haass acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his employment compensation.
  • The inducement stock option award is subject to the terms and conditions of the inducement stock option award agreement covering the grant of the inducement stock options.
  • Syros is redefining the power of small molecules to control the expression of genes.

Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment

Retrieved on: 
Wednesday, October 13, 2021

Its ubiquitous activity and low toxicity have made it challenging to select the most promising clinical targets for this novel compound.

Key Points: 
  • Its ubiquitous activity and low toxicity have made it challenging to select the most promising clinical targets for this novel compound.
  • Professor Bernards commented, We are excited to work with Lixte to identify the most powerful drug combinations of LB-100 for cancer therapy.
  • Our unbiased genetic approach to identify synthetic lethal drug targets of LB-100 has proven its utility in our previous studies.
  • www.lixte.com
    About the Netherlands Cancer Institute, Amsterdam
    The Netherlands Cancer Institute , founded in 1913, is among the worlds best comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care.

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

Retrieved on: 
Wednesday, October 13, 2021

and PARIS, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, and SparingVision, a genomic medicine company developing vision saving treatments for ocular diseases, today announced a strategic collaboration to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases.

Key Points: 
  • and PARIS, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, and SparingVision, a genomic medicine company developing vision saving treatments for ocular diseases, today announced a strategic collaboration to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases.
  • SparingVision will lead and fund the preclinical and clinical development for the genome editing product candidates pursued under the collaboration.
  • Intellia will also maintain the ability to leverage technology advances established under this collaboration for any targets outside the partnership.
  • Please find a link to join this webcast here: https://us02web.zoom.us/j/83682810928
    Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology.

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

Retrieved on: 
Wednesday, October 13, 2021

As part of this collaboration, Intellia will grant SparingVision exclusive rights to Intellias proprietary in vivo CRISPR/Cas9-based genome editing technology for up to three ocular targets addressing diseases with significant unmet medical need.

Key Points: 
  • As part of this collaboration, Intellia will grant SparingVision exclusive rights to Intellias proprietary in vivo CRISPR/Cas9-based genome editing technology for up to three ocular targets addressing diseases with significant unmet medical need.
  • SparingVision will lead and fund the preclinical and clinical development for the genome editing product candidates pursued under the collaboration.
  • Intellia will also maintain the ability to leverage technology advances established under this collaboration for any targets outside the partnership.
  • Please find a link to join this webcast here: https://us02web.zoom.us/j/83682810928
    Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology.

Worldwide Protein Expression Industry to 2028 - by Product, Services, Application, End-user and Geography - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 13, 2021

The global protein expression market is expected to reach US$ 4,000.67 million in 2028 from US$ 2,221.73 million in 2021.

Key Points: 
  • The global protein expression market is expected to reach US$ 4,000.67 million in 2028 from US$ 2,221.73 million in 2021.
  • Protein expression is a process in which proteins are synthesized, modified and regulated.
  • The proteins synthesized using protein expression technique can be used for industrial processes or to diagnose and to treat diseases.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Protein Expression market.

Twist Bioscience and the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research

Retrieved on: 
Wednesday, October 13, 2021

Twist will market this expert-developed exome panel as the Twist Alliance Clinical Research Exome .

Key Points: 
  • Twist will market this expert-developed exome panel as the Twist Alliance Clinical Research Exome .
  • The Twist Alliance Clinical Research Exome helps support the Broad Institute Genomics Platform and was designed using validated data from clinical patient samples.
  • Exome sequencing has long been a key part of our sequencing efforts for large cancer and germline research studies.
  • Well designed, custom target enrichment panels enable increased sequencing depth on target genes while reducing overall sequencing.